Tetragenetics Inc., an Arlington, MA-based biotechnology company engaged in the expression of ion channel drug targets, received an approx. $1.54m grant from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH).
The grant, which will be awarded over two years, will enable the establishment of a public-private partnership between Tetragenetics and the Tetrahymena Stock Center at Cornell University to provide recombinant protein expression services to the not-for-profit research community.
It also supports work that will expand the capabilities of the TetraExpress™ protein production platform including the development of an engineered host strain for drug free selection of transformed cells.
In collaboration with Heptares Therapeutics, the world leader in the production of stabilized G protein-coupled receptors (GPCRs), this grant will allow the two companies to develop optimized methods for high-yield GPCR expression in the TetraExpress™ system.
Led by Dr. Ted Clark, Chief Scientific Officer, Tetragenetics has developed proprietary technology (TetraExpress™) that enables the rapid production of properly folded and functional ion channel proteins in membrane preparations and in purified form for use in antibody discovery and small molecule screening programs.
The company uses these recombinant proteins to discover and develop new drugs for ion channel related autoimmune diseases and pain management.